Lek Pharmaceuticals d.d., Pharmadox Healthcare Limited, Salutas Pharma GmbH
PolandAll drugs from this manufacturer
-
The medicine is used in adults for the treatment of high-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML). These are diseases that affect the bone marrow.
Dosage form: powder for preparation of injection suspension
Active substance Dosage azacitidine 100 mg ATC: L01BC07
-
The medicine is used in adults and children over 6 years of age for the treatment of chronic myeloid leukemia (Ph-positive type) in the newly diagnosed phase, the accelerated phase, or the blast crisis phase, when previous treatment has been ineffective or inappropriate.
Dosage form: tablets, film-coated
Active substance Dosage bosutinib 100 mg ATC: L01EA04
-
The medicine is used in adults and children over 6 years of age for the treatment of chronic myeloid leukemia (Ph-positive type) in the newly diagnosed phase or in patients for whom previous treatment has not been effective. It is also used in adults in the accelerated phase and the blast crisis phase of this disease.
Dosage form: tablets, film-coated
Active substance Dosage bosutinib 400 mg ATC: L01EA04
-
The medicine is used in adults and children over 6 years of age for the treatment of chronic myeloid leukemia (Ph-positive type), when the disease has been newly diagnosed or when previous treatments have not been effective. It is also used in adults in the accelerated phase or blast crisis of this disease.
Dosage form: tablets, film-coated
Active substance Dosage bosutinib 500 mg ATC: L01EA04